Name | Last modified | Size | Description | |
---|---|---|---|---|
Parent Directory | - | |||
ACG-IBD-guideline-1-..> | 2021-03-05 12:09 | 7.7K | ||
ACG-IBD-guideline-1.png | 2021-03-05 12:09 | 9.3K | ||
ACG-IBD-guideline-15..> | 2021-03-05 12:09 | 7.7K | ||
ACG-IBD-guideline-e1..> | 2021-03-05 12:09 | 5.4K | ||
ACG-IBD-guideline-e1..> | 2021-03-05 12:09 | 5.4K | ||
ACG-IBD-guideline-e1..> | 2021-03-05 12:09 | 1.3K | ||
ACG-IBD-guideline-e1..> | 2021-03-05 12:09 | 4.1K | ||
ACG-IBD-guideline.png | 2021-03-05 12:09 | 9.3K | ||
ACG-Preventive-Care-..> | 2021-03-05 12:09 | 7.4K | ||
ACG-Preventive-Care-..> | 2021-03-05 12:09 | 6.2K | ||
AGA-Clinical-practic..> | 2021-03-05 12:09 | 7.9K | ||
AGA-Clinical-practic..> | 2021-03-05 12:09 | 6.6K | ||
AGA-Guidelines-2017-..> | 2021-03-05 12:09 | 8.0K | ||
AGA-Guidelines-2017.png | 2021-03-05 12:09 | 7.4K | ||
AGA-clinical-care-pa..> | 2021-03-05 12:09 | 7.5K | ||
AGA-clinical-care-pa..> | 2021-03-05 12:09 | 7.0K | ||
AGA-guidelins_TDMinI..> | 2021-03-05 12:09 | 7.3K | ||
AGA-guidelins_TDMinI..> | 2021-03-05 12:09 | 5.8K | ||
Allergic-Eosinophili..> | 2021-03-05 12:09 | 12K | ||
Allergic-Eosinophili..> | 2021-03-05 12:09 | 21K | ||
Archive_Severe-Asthm..> | 2019-04-22 18:23 | 7.3M | ||
Ask-AGA-150x150.png | 2021-03-05 12:09 | 7.2K | ||
Ask-AGA-e15436067938..> | 2021-03-05 12:09 | 2.9K | ||
Ask-AGA-e15436069591..> | 2021-03-05 12:09 | 2.9K | ||
Ask-AGA.png | 2021-03-05 12:09 | 5.6K | ||
BRIDGE-Anti-TNF-Opti..> | 2021-03-05 12:09 | 6.6K | ||
BRIDGE-Anti-TNF-Opti..> | 2021-03-05 12:09 | 5.6K | ||
CDC-Adult-Imunizatio..> | 2021-03-05 12:09 | 8.5K | ||
CDC-Adult-Imunizatio..> | 2021-03-05 12:09 | 6.9K | ||
CDC-vaccination-info..> | 2021-03-05 12:09 | 8.2K | ||
CDC-vaccination-info..> | 2021-03-05 12:09 | 7.2K | ||
Dan-Sharp-IBD-150x15..> | 2021-03-05 12:09 | 6.5K | ||
Dan-Sharp-IBD.png | 2021-03-05 12:09 | 5.3K | ||
ECCO_UC_guidelines-2..> | 2021-03-05 12:09 | 7.7K | ||
ECCO_UC_guidelines-2..> | 2021-03-05 12:09 | 6.0K | ||
ECCO_UC_guidelines-2..> | 2021-03-05 12:09 | 6.8K | ||
ECCO_UC_guidelines-2..> | 2021-03-05 12:09 | 6.0K | ||
Foundation-150x150.png | 2021-03-05 12:09 | 7.2K | ||
Foundation.png | 2021-03-05 12:09 | 5.8K | ||
IBD-Chcecklist-for-M..> | 2021-03-05 12:09 | 6.9K | ||
IBD-Chcecklist-for-M..> | 2021-03-05 12:09 | 6.4K | ||
IBD-CheckList-150x15..> | 2021-03-05 12:09 | 6.6K | ||
IBD-CheckList.png | 2021-03-05 12:09 | 5.8K | ||
IBD-manager-mobile-a..> | 2021-03-05 12:09 | 7.6K | ||
IBD-manager-mobile-a..> | 2021-03-05 12:09 | 6.1K | ||
IBD-slide-download-i..> | 2021-03-05 12:09 | 6.3K | ||
IBD-slide-download-i..> | 2021-03-05 12:09 | 3.8K | ||
Integrity-PIA-Sec-1-..> | 2021-03-05 12:09 | 6.3K | ||
Integrity-PIA-Sec-1-..> | 2021-03-05 12:09 | 5.3K | ||
Integrity-PIA-Sec-2-..> | 2021-03-05 12:09 | 7.5K | ||
Integrity-PIA-Sec-2-..> | 2021-03-05 12:09 | 4.3K | ||
Integrity-PIA-Sec-3-..> | 2021-03-05 12:09 | 7.2K | ||
Integrity-PIA-Sec-3-..> | 2021-03-05 12:09 | 5.0K | ||
Integrity-PIA-Sec-4-..> | 2021-03-05 12:09 | 10K | ||
Integrity-PIA-Sec-4-..> | 2021-03-05 12:09 | 7.1K | ||
Integrity-PIA-Sec-5-..> | 2021-03-05 12:09 | 7.6K | ||
Integrity-PIA-Sec-5-..> | 2021-03-05 12:09 | 5.3K | ||
Integrity-PIA-Sec-6-..> | 2021-03-05 12:09 | 8.9K | ||
Integrity-PIA-Sec-6-..> | 2021-03-05 12:09 | 6.7K | ||
Integrity-PIA-Summar..> | 2021-03-05 12:09 | 5.5K | ||
Integrity-PIA-Summar..> | 2021-03-05 12:09 | 2.4K | ||
NICE-UC-Guidelines_2..> | 2021-03-05 12:10 | 6.8K | ||
NICE-UC-Guidelines_2..> | 2021-03-05 12:10 | 5.9K | ||
Nonallergic-Eosinoph..> | 2021-03-05 12:10 | 12K | ||
Nonallergic-Eosinoph..> | 2021-03-05 12:10 | 21K | ||
Overcoming-Barriers-..> | 2021-03-05 12:10 | 7.6K | ||
Overcoming-Barriers-..> | 2021-03-05 12:10 | 6.6K | ||
PAH_HMS_279x192-150x..> | 2021-03-05 12:10 | 8.3K | ||
PAH_HMS_279x192.jpg | 2021-03-05 12:10 | 37K | ||
PAH_HMS_1800x242-1-1..> | 2021-03-05 12:10 | 1.2K | ||
PAH_HMS_1800x242-1-3..> | 2021-03-05 12:10 | 2.2K | ||
PAH_HMS_1800x242-1-7..> | 2021-03-05 12:10 | 8.6K | ||
PAH_HMS_1800x242-1-1..> | 2021-03-05 12:10 | 14K | ||
PAH_HMS_1800x242-1.jpg | 2021-03-05 12:10 | 66K | ||
PE_AARC_279x192-150x..> | 2021-03-05 12:10 | 8.1K | ||
PE_AARC_279x192.jpg | 2021-03-05 12:10 | 35K | ||
Practive-Parameters_..> | 2021-03-05 12:10 | 7.7K | ||
Practive-Parameters_..> | 2021-03-05 12:10 | 7.2K | ||
Restroom-request-150..> | 2021-03-05 12:10 | 7.5K | ||
Restroom-request.png | 2021-03-05 12:10 | 6.9K | ||
Session-1-1-150x150.png | 2021-03-05 12:10 | 12K | ||
Session-1-1-300x169.png | 2021-03-05 12:10 | 23K | ||
Session-1-1-768x432.png | 2021-03-05 12:10 | 95K | ||
Session-1-1.png | 2021-03-05 12:10 | 131K | ||
Session-1-DET-150x15..> | 2021-03-05 12:10 | 12K | ||
Session-1-DET-300x16..> | 2021-03-05 12:10 | 23K | ||
Session-1-DET-768x43..> | 2021-03-05 12:10 | 96K | ||
Session-1-DET.png | 2021-03-05 12:10 | 133K | ||
Session-1-ORL-150x15..> | 2021-03-05 12:10 | 12K | ||
Session-1-ORL-300x16..> | 2021-03-05 12:10 | 23K | ||
Session-1-ORL-768x43..> | 2021-03-05 12:10 | 96K | ||
Session-1-ORL.png | 2021-03-05 12:10 | 133K | ||
Session-1-Value-in-H..> | 2018-11-29 18:24 | 935K | ||
Session-1-Value-in-H..> | 2018-11-29 20:28 | 934K | ||
Session-1-Value-in-H..> | 2018-11-27 16:36 | 934K | ||
Session-2-150x150.png | 2021-03-05 12:10 | 12K | ||
Session-2-300x169.png | 2021-03-05 12:10 | 24K | ||
Session-2-768x432.png | 2021-03-05 12:10 | 100K | ||
Session-2-COPD.pdf | 2018-11-27 16:53 | 1.7M | ||
Session-2-DET-150x15..> | 2021-03-05 12:10 | 13K | ||
Session-2-DET-300x16..> | 2021-03-05 12:10 | 24K | ||
Session-2-DET-768x43..> | 2021-03-05 12:10 | 99K | ||
Session-2-DET.png | 2021-03-05 12:10 | 138K | ||
Session-2-ORL-150x15..> | 2021-03-05 12:10 | 13K | ||
Session-2-ORL-300x16..> | 2021-03-05 12:10 | 24K | ||
Session-2-ORL-768x43..> | 2021-03-05 12:10 | 99K | ||
Session-2-ORL.png | 2021-03-05 12:10 | 138K | ||
Session-2-T2DM-DET.pdf | 2018-11-29 18:38 | 1.5M | ||
Session-2-T2DM-ORL.pdf | 2018-11-29 20:28 | 1.6M | ||
Session-2.png | 2021-03-05 12:10 | 138K | ||
Session-3-150x150.png | 2021-03-05 12:10 | 13K | ||
Session-3-300x169.png | 2021-03-05 12:10 | 23K | ||
Session-3-768x432.png | 2021-03-05 12:10 | 99K | ||
Session-3-DET-150x15..> | 2021-03-05 12:10 | 13K | ||
Session-3-DET-300x16..> | 2021-03-05 12:10 | 23K | ||
Session-3-DET-768x43..> | 2021-03-05 12:10 | 99K | ||
Session-3-DET.png | 2021-03-05 12:10 | 132K | ||
Session-3-HE-DET.pdf | 2018-11-29 18:24 | 813K | ||
Session-3-HE-ORL.pdf | 2018-11-29 20:28 | 813K | ||
Session-3-HE.pdf | 2018-11-27 16:53 | 813K | ||
Session-3-ORL-150x15..> | 2021-03-05 12:10 | 13K | ||
Session-3-ORL-300x16..> | 2021-03-05 12:10 | 23K | ||
Session-3-ORL-768x43..> | 2021-03-05 12:10 | 99K | ||
Session-3-ORL.png | 2021-03-05 12:10 | 132K | ||
Session-3.png | 2021-03-05 12:10 | 132K | ||
Session-4-150x150.png | 2021-03-05 12:10 | 12K | ||
Session-4-300x169.png | 2021-03-05 12:10 | 23K | ||
Session-4-768x432.png | 2021-03-05 12:10 | 97K | ||
Session-4-COPD-ORL.pdf | 2018-11-29 20:28 | 1.0M | ||
Session-4-CTEPH-DET.pdf | 2018-11-29 18:24 | 1.5M | ||
Session-4-DET-150x15..> | 2021-03-05 12:10 | 13K | ||
Session-4-DET-300x16..> | 2021-03-05 12:10 | 24K | ||
Session-4-DET-768x43..> | 2021-03-05 12:10 | 100K | ||
Session-4-DET.png | 2021-03-05 12:10 | 135K | ||
Session-4-HF.pdf | 2018-11-27 16:53 | 1.3M | ||
Session-4-ORL-150x15..> | 2021-03-05 12:10 | 12K | ||
Session-4-ORL-300x16..> | 2021-03-05 12:10 | 24K | ||
Session-4-ORL-768x43..> | 2021-03-05 12:10 | 100K | ||
Session-4-ORL.png | 2021-03-05 12:10 | 138K | ||
Session-4.png | 2021-03-05 12:10 | 136K | ||
Session-5-DET-150x15..> | 2021-03-05 12:10 | 12K | ||
Session-5-DET-300x16..> | 2021-03-05 12:10 | 24K | ||
Session-5-DET-768x43..> | 2021-03-05 12:10 | 98K | ||
Session-5-DET.png | 2021-03-05 12:10 | 136K | ||
Session-5-HF-DET.pdf | 2018-11-29 18:24 | 1.3M | ||
Session-5-HF-ORL.pdf | 2018-11-29 20:28 | 1.5M | ||
Session-5-ORL-150x15..> | 2021-03-05 12:10 | 12K | ||
Session-5-ORL-300x16..> | 2021-03-05 12:10 | 24K | ||
Session-5-ORL-768x43..> | 2021-03-05 12:10 | 98K | ||
Session-5-ORL.png | 2021-03-05 12:10 | 136K | ||
Session-6-COPD-DET.pdf | 2018-11-29 18:24 | 1.0M | ||
Session-6-DET-150x15..> | 2021-03-05 12:10 | 12K | ||
Session-6-DET-300x16..> | 2021-03-05 12:10 | 24K | ||
Session-6-DET-768x43..> | 2021-03-05 12:10 | 100K | ||
Session-6-DET.png | 2021-03-05 12:10 | 138K | ||
Severe-asthmaBioDigi..> | 2021-03-05 12:10 | 3.3K | ||
Severe-asthmaBioDigi..> | 2021-03-05 12:10 | 10K | ||
UC-Guidelines-List-1..> | 2021-03-05 12:10 | 7.0K | ||
UC-Guidelines-List.png | 2021-03-05 12:10 | 5.8K | ||
Vendolizumab-as-main..> | 2021-03-05 12:10 | 7.8K | ||
Vendolizumab-as-main..> | 2021-03-05 12:10 | 6.8K | ||
WGO-IBD-Guidelines_2..> | 2021-03-05 12:10 | 6.8K | ||
WGO-IBD-Guidelines_2..> | 2021-03-05 12:10 | 6.0K | ||
ask-AGA-patient-guid..> | 2021-03-05 12:09 | 8.1K | ||
ask-AGA-patient-guid..> | 2021-03-05 12:09 | 7.0K | ||
cert_sign-150x58.jpg | 2021-03-05 12:09 | 3.0K | ||
cert_sign.jpg | 2021-03-05 12:09 | 4.5K | ||
certbullet.jpg | 2021-03-05 12:09 | 529 | ||
customizable-letter-..> | 2021-03-05 12:09 | 7.2K | ||
customizable-letter.png | 2021-03-05 12:09 | 6.2K | ||
dr-discussion-guide-..> | 2021-03-05 12:09 | 7.1K | ||
dr-discussion-guide.png | 2021-03-05 12:09 | 5.8K | ||
ibd-and-me-150x150.png | 2021-03-05 12:09 | 8.2K | ||
ibd-and-me-e15436058..> | 2021-03-05 12:09 | 3.3K | ||
ibd-and-me.png | 2021-03-05 12:09 | 6.8K | ||
ibd-commuity-list-15..> | 2021-03-05 12:09 | 7.3K | ||
ibd-commuity-list.png | 2021-03-05 12:09 | 6.4K | ||
ibd-support-foundati..> | 2021-03-05 12:09 | 6.6K | ||
ibd-support-foundati..> | 2021-03-05 12:09 | 6.3K | ||
ill-be-determind-150..> | 2021-03-05 12:09 | 7.2K | ||
ill-be-determind.png | 2021-03-05 12:09 | 5.7K | ||
inflamed-untamed-150..> | 2021-03-05 12:09 | 8.8K | ||
inflamed-untamed.png | 2021-03-05 12:09 | 7.7K | ||
just-like-me-and-ibd..> | 2021-03-05 12:10 | 8.4K | ||
just-like-me-and-ibd..> | 2021-03-05 12:10 | 7.8K | ||
optimizing-benefit-o..> | 2021-03-05 12:10 | 8.2K | ||
optimizing-benefit-o..> | 2021-03-05 12:10 | 7.0K | ||
patients-like-me-150..> | 2021-03-05 12:10 | 7.0K | ||
patients-like-me.png | 2021-03-05 12:10 | 5.6K | ||
pharma-Financial-ass..> | 2021-03-05 12:10 | 7.2K | ||
pharma-Financial-ass..> | 2021-03-05 12:10 | 5.2K | ||
pubinaction.zip | 2018-11-20 10:55 | 880K | ||
trial-finder-150x150..> | 2021-03-05 12:10 | 8.0K | ||
trial-finder.png | 2021-03-05 12:10 | 6.0K | ||
you-and-ibd-150x150.png | 2021-03-05 12:10 | 8.3K | ||
you-and-ibd.png | 2021-03-05 12:10 | 7.4K | ||